Posted: Wednesday, September 20, 2017
Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, and Noopur S. Raje, MD, of the Massachusetts General Hospital Cancer Center, discuss the impact of denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease.